The history and future of targeting cyclin-dependent kinases in cancer therapy
Open accessThe DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Abstract
Cancer represents a pathological manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies. In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle. Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events. Translating this knowledge into successful clinical development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clinical trials. Here, we review the biology of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clinical results of CDK inhibitors. We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clinical activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Grade 3–4 neutropenia is observed in approximately 60% of patients taking palbociclib and ribociclib (Asghar et al., 2015; Hortobagyi et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like palbociclib, these orally-bioavailable and highly selective CDK4/6-targeting agents exhibit IC50 values in the low nanomolar range, whereas other CDK family members are far less sensitive (1, 88, 89).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Such pan-CDK inhibitors had limited success, due in part to the dose limiting toxicities that hampered their use (Asghar et al., 2015).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“More than two decades after discovery of CDK4 and CDK6, drugs inhibiting their activities are now demonstrating significant efficacy in cancer treatment [for other recent reviews, see (1-3)].”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
In the citing paper
“Abemaciclib appears to be better tolerated overall, with only 55% of patients experiencing significant adverse events (as compared to 70–80% with ribociclib and palbociclib) and only 21% with grade 3–4 neutropenia.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
Cited by
Items 901–1,000 of 1,002
Baş, O., Erul, E., Güven, D. C., & Aksoy, S. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-07320-y · Cited by 16
Rugo, H. S., Im, S., Joy, A. A., Shparyk, Y. V., Walshe, J. M., Sleckman, B. G., Loi, S., Theall, K. P., Kim, S., Huang, X., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.11.005 · Cited by 16
“CDKs, particularly CDK4 and CDK6 (CDK4/6), regulate cell cycle progression from the G0 or G1 phase into the S phase by phosphorylating the tumor suppressor gene retinoblastoma and other related proteins like p107 and p130 [1,3].”
BackgroundTranscription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy
Wu, W., Yu, S., & Yu, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188842 · Cited by 16
Targeting cyclin D1 as a therapeutic approach for papillary thyroid carcinoma
Cai, W. L., Shu, L.-Z., Liu, D.-J., Zhou, L., Wang, M.-M., & Deng, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1145082 · Cited by 16
Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era
Moding, E. J., Mowery, Y. M., & Kirsch, D. G. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000203 · Cited by 16
Nekardová, M., Vymětalová, L., Khirsariya, P., Kováčová, S., Hylsová, M., Jorda, R., Kryštof, V., Fanfrlík, J., Hobza, P., & Paruch, K. (2017) · ChemPhysChem · doi:10.1002/cphc.201601319 · Cited by 16
Autophagy is essential for flavopiridol-induced cytotoxicity against MCF-7 breast cancer cells
Wang, S., Wang, K., Wang, H., Han, J., & Sun, H. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7815 · Cited by 16
“Continued investigations into the role of dysregulated cell cycling in human breast cancer have led to the identification of several therapeutically attractive targets (3,4).”
Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment
Rozpędek‐Kamińska, W., Pytel, D., Nowak-Zduńczyk, A., Lewko, D., Wojtczak, R., Diehl, J. A., & Majsterek, I. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180117102233 · Cited by 16
Ajani, H., Jansa, J., Köprülüoğlu, C., Hobza, P., Kryštof, V., Lyčka, A., & Lepšík, M. (2018) · Journal of Molecular Recognition · doi:10.1002/jmr.2720 · Cited by 16
“For these reasons, CDKs have become important targets for anticancer drug development.(4) CDK structure features the N‐terminal β‐sheet and C‐terminal α‐helical domains joined by the hinge region with an active‐site cleft in between, which binds the ATP molecule.”
BackgroundLee, K., Chung, K., Lee, J., Choi, J., Choi, S. Y., Kim, S., Lee, J. Y., & Lee, K. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.11.062 · Cited by 16
Bae, H., Go, Y.-H., Kwon, T., Sung, B. J., & Cha, H. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2570-2 · Cited by 16
Overexpression of cyclin‐dependent kinase 4 protein in extramammary Paget's disease
Urata, K., Kajihara, I., Myangat, T. M., Tasaki, Y., Otsuka‐Maeda, S., Sawamura, S., Yamada‐Kanazawa, S., Sakamoto, R., Makino, K., Aoi, J., et al. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.14858 · Cited by 16
Malumbres, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00004-9 · Cited by 17
Yuan, K., Min, W., Wang, X., Li, J., Kuang, W., Zhang, F., Xie, S., & Yang, P. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0011 · Cited by 16
Faber, E. B., Tian, D., Burban, D. J., Levinson, N. M., Hawkinson, J. E., & Georg, G. I. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00169 · Cited by 16
Ni, J., Chen, Y., Fei, B., Zhu, Y., Du, Y., Liu, L., Guo, L., & Zhu, W. (2021) · Gynecologic and Obstetric Investigation · doi:10.1159/000513070 · Cited by 16
The Development of 3-substituted Indolin-2-one Derivatives as Kinase Inhibitors for Cancer Therapy
Xu, C., Liu, Y., & Zhao, G. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210831142311 · Cited by 16
Dittmar, Y., & Settmacher, U. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i11.292 · Cited by 16
Chemical fragment-based CDK4/6 inhibitors prediction and web server
Wang, L., Li, Y., Xu, M., Pang, X., Liu, Z., Tan, W., & Xu, J. (2016) · RSC Advances · doi:10.1039/c5ra23289a · Cited by 16
Ali, A. M., Tawfik, S. S., Bhongade, B. A., Massoud, M. A. M., & Mostafa, A. S. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.137215 · Cited by 15
Innovating Cancer Treatment Through Cell Cycle, Telomerase, Angiogenesis, and Metastasis
Yousefi, T., Jobani, B. M., Taebi, R., & Qujeq, D. (2024) · DNA and Cell Biology · doi:10.1089/dna.2024.0109 · Cited by 15
“C ancer, a multifaceted and formidable adversary, continues to pose a signi fi cant challenge to modern medicine (Asghar et al., 2015).”
Dajsakdipon, T., Susiriwatananont, T., Wongkraisri, C., Ithimakin, S., Parinyanitikul, N., Supavavej, A., Dechaphunkul, A., Sunpaweravong, P., Neesanun, S., Akewanlop, C., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12765-x · Cited by 15
“Consequently, cancer cells divide rapidly and metastasize [6].”
BackgroundShirani, N., Abdi, N., Chehelgerdi, M., Yaghoobi, H., & Chehelgerdi, M. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1485422 · Cited by 15
Design, synthesis and biological evaluation of dual CDK9/PARP inhibitors for the treatment of cancer
Huang, J., He, Y., Chen, S., Ren, R., Zhang, J., Zhang, J.-Q., Zhang, Z., Chen, T., & Wang, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117367 · Cited by 15
Yang, J., Chang, Y., Zhou, K., Huang, W., Tien, J. C.-Y., Zhang, P., Liu, W., Zhou, L., Zhou, Y., Ren, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00127 · Cited by 15
Wu, R.-Z., Sun, Q.-Q., Fu, Y., Yu, H.-N., Liu, W.-Y., Wu, Y., Zhang, H., Pan, Y.-L., & Xin, R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1507845 · Cited by 15
“Additionally, CDK1 promotes tumor development and enhances drug resistance by in fl uencing cell morphology, motility, and apoptosis (39, 50, 51).”
YEŞİL, T. A., Dilek, Ö., & Tilki, T. (2025) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2025.101764 · Cited by 15
Rossi, L. A., McCartney, A., Risi, E., Santo, I. D., Migliaccio, I., Malorni, L., Biganzoli, L., & Leo, A. D. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.05.019 · Cited by 16
Peyressatre, M., Arama, D. P., Laure, A., Gonzalez‐Vera, J. A., Pellerano, M., Masurier, N., Lisowski, V., & Morris, M. C. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00691 · Cited by 15
“Since the mechanism of action of ATP-competitive inhibitors is notorious for its lack of selectivity, resulting in a variety of undesirable secondary effects, alternative strategies have been deployed to identify compounds that target sites other than the ATP-binding pocket or the catalytic site and thereby enable dev…”
BackgroundHossian, A. K. M. N., Mackenzie, G. G., & Mattheolabakis, G. (2021) · Oncology Reports · doi:10.3892/or.2021.7953 · Cited by 15
“CDK1 is a critical protein for that transition and the completion of cell cycle progression (8,27,28).”
Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma
Shi, C.-J., Xu, S.-M., Han, Y., Zhou, R., & Zhang, Z.-Y. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000777 · Cited by 15
Wang, W., Cui, X.-W., Gu, Y., Wei, C., Li, Y.-H., Ren, J.-Y., Chung, M., Aimaier, R., Zhang, H., Li, Q. F., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.07.164 · Cited by 15
“CDKis have critical roles in regulating cell proliferation and transcription in tumor cells (Asghar et al., 2015).”
BackgroundDiscovery of novel benzofuro[3,2-b]quinoline derivatives as dual CDK2/Topo I inhibitors
Huang, Y., Liu, W., Huang, S., Li, D., Xu, C., Jiang, X., Liu, M., Liu, X., Zhu, C., Wu, L., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105870 · Cited by 15
Trained Immunity of IL-12-, IL-15-, and IL-18-Induced CD3+CD56+ NKT-Like Cells
Zhu, S., Zhang, C., Sun, Q., Wang, Y., Yu, W., Wei, F., & Ren, X. (2022) · Journal of Oncology · doi:10.1155/2022/8724933 · Cited by 15
“Hartwell, play an important role in the initiation of cell cycle and the regulation of cell cycle transition [21, 22].”
BackgroundDiscovery of 5,7-Dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-ones as Highly Selective CDK2 Inhibitors
Sokolsky, A., Winterton, S., Kennedy, K., Drake, K., Stump, K., Huo, L., Lo, Y. Y. C., Ye, M., Covington, M. B., Diamond, S., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00408 · Cited by 15
Giordano, F., D’Amico, M., Montalto, F. I., Malivindi, R., Chimento, A., Conforti, F. L., Pezzi, V., Panno, M. L., Andò, S., & Amicis, F. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210094 · Cited by 15
“The founding discoveries in the early 1990s provided proof of principle that Cdk4 inhibition might retard cancer cell development [33].”
BackgroundRecent Progress of Cyclin-Dependent Kinase Inhibitors as Potential Anticancer Agents
Li, T., Weng, T., Zuo, M., Wei, Z., Chen, M., & Li, Z. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0129 · Cited by 15
Park, S. J., Kim, E., Yoo, M., Lee, J., Park, C. H., Hwang, J. Y., & Ha, J. D. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.08.018 · Cited by 15
“In mammalian cells, CDK1 complexed with cyclin A/B controls progression from G2- to Mphase; CDK4 and CDK6 complexed with cyclin D controls progression from G1- to S-phase, leading to the initiation of DNA synthesis; and CDK2 complexed with cyclin E/A promotes completion of the process of DNA synthesis in S-phase.(3) C…”
A systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancer
Gasa, L., Sánchez-Botet, A., Quandt, E., Hernández-Ortega, S., Jiménez, J., Carrasco-García, M. À., Simonetti, S., Kron, S. J., Ribeiro, M. P. C., Nadal, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10770-8 · Cited by 15
Prognostic Value of RNASEH2A-, CDK1-, and CD151-Related Pathway Gene Profiling for Kidney Cancers
Yang, C., Huang, H., Yen, J.-C., & Chang, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061586 · Cited by 15
“However, the results from clinical trials for CDK inhibitors were mostly disappointing [15].”
Novel dodecyl-containing azido and glucuronamide-based nucleosides exhibiting anticancer potential
Xavier, N. M., Gonçalves‐Pereira, R., Jorda, R., Hendrychová, D., & Oliveira, M. C. (2019) · Pure and Applied Chemistry · doi:10.1515/pac-2019-0106 · Cited by 15
Predicting the survival of patients with lung adenocarcinoma using a four‑gene prognosis risk model
Zhang, W., Shen, Y., & Feng, G. (2019) · Oncology Letters · doi:10.3892/ol.2019.10366 · Cited by 15
“Cyclin‐dependent kinases mediate the onset of mitosis, cell cycle commitment and DNA synthesis, which are involved in tumor development and are potential targets for cancer treatment (37,38).”
BackgroundGao, X., Zhang, Y., Zhang, R., Zhao, Z., Zhang, H., Wu, J., Shen, W., & Zhong, M. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7883 · Cited by 15
“CDK1 serves an important role in the control of the cell cycle by regulating the centrosome cycle, promoting G2-M transition and modulating G1 phase progression (7).”
BackgroundShort- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer
Kietzman, W. B., Graham, G. T., Ory, V., Sharif, G. M., Kushner, M. H., Gallanis, G. T., Kallakury, B., Wellstein, A., & Riegel, A. T. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0231 · Cited by 15
Lee, K. A., Shepherd, S. T. C., & Johnston, S. R. D. (2019) · Future Oncology · doi:10.2217/fon-2019-0169 · Cited by 16
LncRNA LINC00974 Upregulates CDK6 to Promote Cell Cycle Progression in Gastric Carcinoma
Gao, H., Yin, Y., Qian, A., Guo, R., & Qi, J. (2019) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2019.2904 · Cited by 15
“10 Therefore, inhibiting the expression of CDKs is a potential target for cancer therapies.”
Roy, E., Wong, H. Y., Villani, R. M., Rouillé, T., Salik, B., Sim, S.-L., Murigneux, V., Stark, M. S., Fink, J. L., Soyer, H. P., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107702 · Cited by 15
Li, J., Zhou, Y., Yan, Y., Zheng, Z., Hu, Y., & Wu, W. (2020) · Aging · doi:10.18632/aging.103537 · Cited by 15
Zhu, Y., Ke, K., Xia, Z.-K., Li, H., Su, R., Dong, C., Zhou, F.-M., Wang, L., Chen, R., Wu, S., et al. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00269-4 · Cited by 15
Mansour, H. S., El-wahab, H. A. A. A., Ali, A. M., & Aboul‐Fadl, T. (2021) · RSC Advances · doi:10.1039/d0ra10672k · Cited by 15
Small-Molecule Degraders of Cyclin-Dependent Kinase Protein: A Review
Yu, B., Du, Z., Zhang, Y., Li, Z., & Bian, J. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0154 · Cited by 15
Noonan, J., Jarzabek, M. A., Lincoln, F. A., Cavanagh, B., Pariag, A. R., Jurić, V., Young, L. S., Ligon, K. L., Jahns, H., Zheleva, D. I., et al. (2019) · Cancers · doi:10.3390/cancers11122005 · Cited by 15
“Of the first-generation inhibitors, flavopiridol is the most extensively investigated [40].”
BackgroundInfluentialIntroduction to Cell Cycle and Its Regulators
Mir, M. A., & Jan, A. (2023) · Springer eBooks · doi:10.1007/978-981-19-8911-7_3 · Cited by 14
Pharmacological potential of micheliolide: A focus on anti-inflammatory and anticancer activities
Uddin, J., Fatima, M., Riaz, A., Kamal, G. M., Muhsinah, A. B., Ahmed, A., & Iftikhar, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27299 · Cited by 14
“As cancerous cells are characterized by prompt and unrestrained cell division [77], these naturally derived compounds are auspiciously capable of deterring the activity of cyclins and cyclin-dependent kinases, together with several protein factors and enzymes, regulating the cell cycle, helping…”
BackgroundIntegrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies
Jovanović, B., Church, S., Gorman, K. M., North, K., Richardson, E. T., DiLullo, M. K., Attaya, V., Kasparian, J., Mohammed-Abreu, A., Kirkner, G. J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1242 · Cited by 14
“…and/or mRNA) and other parameters in TNBC. Transcriptomic profiling has uncovered the presence of several TNBC subtypes including the luminal androgen receptor (LAR) subtype (17, 18), and preclinical studies have suggested that LAR cell lines are sensitive to CDK4/6 inhibition in vitro (19).”
Attia, M. H., Lasheen, D. S., Samir, N., Taher, A. T., Abdel‐Aziz, H. A., & Ella, D. A. A. E. (2024) · Pharmaceuticals · doi:10.3390/ph17121667 · Cited by 14
“Ribociclib was incorporated as a standard reference drug and positive control for the experiment [47].”
Hao, Q., Zhao, W., Li, Z., Lai, Y., Wang, Y., Yang, Q., & Zhang, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117465 · Cited by 14
Zhang, X., Liang, H., Liao, Z., Tong, B., Wu, D., Ma, L., Lei, J., Zhou, X., Zhu, D., Ou, Z., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu6860 · Cited by 14
“M phase ( 13 , 15 ).”
Genomics and advances towards precision medicine for head and neck squamous cell carcinoma
Waes, C. V., & Musbahi, O. (2017) · Laryngoscope Investigative Otolaryngology · doi:10.1002/lio2.86 · Cited by 14
“With increasing numbers of CDK inhibitors being developed this is an area of future promise.(46) Table 1 summarizes trials of CDK inhibitor and combinations registered in ClinicalTrials.”
BackgroundBisphenol B stimulates Leydig cell proliferation but inhibits maturation in late pubertal rats
Li, Y., Yan, H., Yu, Y., Zou, C., Tian, L., Xin, X. L., Zhang, S., Li, Z., Ma, F., & Ge, R. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.112248 · Cited by 14
CRISPR/Cas9-mediated activation of CDH1 suppresses metastasis of breast cancer in rats
Al-Mulhim, F. A., Alqosaibi, A. I., Al-Muhnna, A., Farid, K., Abdel-Ghany, S. E., Rizk, H., Prince, A. M., Isichei, A. C., & Sabit, H. (2021) · Electronic Journal of Biotechnology · doi:10.1016/j.ejbt.2021.06.002 · Cited by 14
Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges
Reinius, M., & Smyth, E. C. (2021) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2021.3 · Cited by 14
CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer
Sang, X., Belmessabih, N., Wang, R., Stephen, P., & Lin, S. (2022) · Cancers · doi:10.3390/cancers14040989 · Cited by 14
“A major concern with a CDK-targeting agent is toxicity: low selectivity underlies the primary cause of failure in the majority of clinical trials [17,19].”
BackgroundPyrazolopyrimidines as attractive pharmacophores in efficient drug design: A recent update
Dorababu, A. (2022) · Archiv der Pharmazie · doi:10.1002/ardp.202200154 · Cited by 14
Chen, H., Hu, K., Xie, Y., Qi, Y., Li, W., He, Y., Fan, S., Liu, W., & Li, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137385 · Cited by 14
“In clinical or preclinical trials, these inhibitors demonstrate significant inhibition on malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, hepatocellular carcinoma and gastrointestinal stromal tumor [42,45,52].”
BackgroundInfluentialLi, K., Huang, G., Wang, Z., Yang, R., Zhang, W., Ni, B., Guan, J., Yi, G., Li, Z., Zhu, Q., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166571 · Cited by 14
Kuznetcova, I., Ostojić, M., Gligorijević, N., Aranđelović, S., & Arion, V. B. (2022) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.2c03134 · Cited by 14
Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction
Tong, J., Tan, X., Hao, S., Ermine, K., Lu, X. Y., Liu, Z., Jha, A., Yu, J., & Zhang, L. (2023) · Oncogene · doi:10.1038/s41388-023-02598-6 · Cited by 14
“RESULTS CDKIs induce DR5 expression in CRC cells with different p53 status To investigate the effects of CDKIs in CRC cells, we treated p53-WT HCT116 CRC cells with first-generation CDKIs flavopiridol (FVP; CDK1/2/4/5/9 inhibitor) and roscovitine (CDK1/2/5/7/9 inhibitor), and second-generation CDKIs dinaciclib (CDK1/2…”
BackgroundMethodResultInfluentialFang, L., Chu, M., Yan, C., Liu, Y., & Zhao, Z. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117263 · Cited by 14
Bakri, Y. E., Karthikeyan, S., Lai, C., Bakhite, E. A.-G., Ahmad, I., Abdel-Rahman, A. E., Abuelhassan, S., Marae, I. S., Mohamed, S. K., & Mague, J. T. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2224899 · Cited by 14
“…(Jain et al., 2011), bisindoles (Mapelli et al., 2005; Mazanetz & Fischer, 2007), aloisines (Mettey et al., 2003), quinazolinone (Helal et al., 2004), aminothiazoles (Kaller et al., 2009), paullones (Kunick et al., 2004; Stukenbrock et al., 2008), and other common inhibitors (Asghar et al., 2015).”
BackgroundZhao, J. J., Fong, K. Y., Chan, Y. H., Tey, J. C. S., Dawood, S. S., Lee, S. C., Finn, R. S., Sundar, R., & Lim, J. S. J. (2023) · Cancers · doi:10.3390/cancers15184558 · Cited by 14
“Both palbociclib and ribociclib are derived from a similar pyrido[2,3-d]-pyrimidin-7-one scaffold that was optimized for selectivity toward CDK4/6 [21], and pre-clinical benchwork has shown similar potencies in terms of CDK4 and CDK6 inhibition [22].”
BackgroundPROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives
Vicente, A. T. S., & Salvador, J. A. R. (2024) · MedComm · doi:10.1002/mco2.575 · Cited by 14
“143,144,148 Furthermore, the occurrence of resistance due to point mutations in CDK6, as well as these inhibitors only affect the kinase-dependent functions of CDK6, are some of the shortcomings associated with CDK6i.”
BackgroundCDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2 + Breast Cancer
Malumbres, M. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.016 · Cited by 14
“The success of cyclin-dependent kinase (CDK)4 and CDK6 inhibitors in treating estrogen receptor (ER)-positive breast cancer is the culmination of more than 15 years of research on the therapeutic possibilities offered by the inhibition of these kinases (Asghar et al., 2015).”
BackgroundHuang, X., Zhou, W., Zhang, Y., & Liu, Y. (2016) · BioMed Research International · doi:10.1155/2016/5230642 · Cited by 14
“CDK1/cyclin B1 protein kinase complex plays a key role in promoting G2M transition via association with multiple interphase cyclins [49–51].”
BackgroundRetractedMulti-step virtual screening to develop selective DYRK1A inhibitors
Koyama, T., Yamaotsu, N., Nakagome, I., Ozawa, S.-I., Yoshida, T., Hayakawa, D., & Hirono, S. (2017) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2017.01.014 · Cited by 14
Synthesis and Anti-Proliferative Effects of Mono- and Bis-Purinomimetics Targeting Kinases
Bistrović, A., Harej, A., Grbčić, P., Sedić, M., Pavelić, S. K., Cetina, M., & Raić‐Malić, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112292 · Cited by 14
Combination Therapies in Advanced, Hormone Receptor–Positive Breast Cancer
Olson, E. A. (2018) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2018.9.1.3 · Cited by 14
“By selectively inhibiting CDK4/6, palbociclib blocks the phosphorylation of downstream proteins essential for entry into the cell cycle (Asghar et al., 2015).”
BackgroundGuo, L., Hu, Y., Chen, X., Li, Q., Wei, B., & Ma, X. (2019) · Cancer Medicine · doi:10.1002/cam4.1970 · Cited by 14
Tubeimoside-1, Triterpenoid Saponin, as a Potential Natural Cancer Killer
Zafar, M. N., Sarfraz, I., Rasul, A., Jabeen, F., Samiullah, K., Hussain, G., Riaz, A., & Ali, M. Z. (2018) · Natural Product Communications · doi:10.1177/1934578x1801300530 · Cited by 14
“Tubeimoside-1 and cell cycle arrest: Since, rapid and uncontrolled cellular division is a key trait of cancer cells [32], therefore, natural bioactive compounds inhibiting mitosis or controlling cell cycle are proved to be attractive candidates for novel anti-cancer therapies [33, 34].”
BackgroundLiu, X., Hu, J., Song, X., Utpatel, K., Zhang, Y., Wang, P., Lu, X., Zhang, J., Xu, M. M., Su, T., et al. (2019) · Cancers · doi:10.3390/cancers11070930 · Cited by 14
“Deregulation of cell cycle results in unconstrained cell division, leading to continuous proliferation, and represents a pivotal driver of carcinogenesis [27].”
BackgroundShrimp miRNA suppresses the stemness of human cancer stem cells via the PIN1 pathway
Zhang, S., & Zhang, X. (2019) · The FASEB Journal · doi:10.1096/fj.201900395rr · Cited by 14
Tang, H., Xu, L., Cen, X., Yang, L., Feng, J., Li, G., Zhu, H., Gao, S., Yu, Y., Zhao, Y., et al. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4553 · Cited by 14
“Cyclin‐dependent kinases (CDKs) are a group of serine/threonine protein kinases family members whose main biological functions are to regulate the cell cycle and transcription (1,2).”
van Caloen, G., Schmitz, S., van Marcke, C., Caignet, X., Mendola, A., Ruys, S. P. D., Roger, P. P., Vertommen, D., & Machiels, J. (2021) · Cancers · doi:10.3390/cancers13061251 · Cited by 14
Protein Kinase Inhibitors - Selectivity or Toxicity?
Grossman, M., & Adler, E. (2021) · Biochemistry · doi:10.5772/intechopen.98640 · Cited by 15
Wu, A. T. H., Huang, H., Wen, Y.-T., Lawal, B., Mokgautsi, N., Huynh, T.-T., Hsiao, M., & Li, W. (2021) · Cells · doi:10.3390/cells10092391 · Cited by 14
Abate, A., Rossini, E., Tamburello, M., Laganà, M., Cosentini, D., Grisanti, S., Fiorentini, C., Tiberio, G. A. M., Scatolini, M., Grosso, E., et al. (2021) · Endocrinology · doi:10.1210/endocr/bqab248 · Cited by 14
Ma, X., Wang, D., Feng, X., Liu, Y., Li, J., & Yang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837217 · Cited by 14
“reducing the expression of Ccnd1 through antisense technology causes a concomitant decline in Ccnd1-dependent kinase activity and results in inhibition of tumor growth, abolition of tumorigenicity, or, in some instances, tumor cell death (Kozar, 2004; Asghar et al., 2015; Sherr et al., 2016; Goel et al., 2017).”
BackgroundCyclin-Dependent Kinase 4/6 Inhibitors Against Breast Cancer
Ateş‐Alagöz, Z., & Hassan, M. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220606095540 · Cited by 14
Development and Strategies of CDK4/6 Inhibitors
Chen, P., Xu, Y., Li, X., Yao, H., & Lin, K. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0062 · Cited by 14
Manimaran, A., Buddhan, R., & Manoharan, S. (2017) · African Journal of Traditional Complementary and Alternative Medicines · doi:10.21010/ajtcam.v14i2.10 · Cited by 14
The Role of CD4/6 Inhibitors in Breast Cancer Treatment
Purohit, L., Jones, C. X., Gonzalez, T., Castrellon, A. B., & Hussein, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021242 · Cited by 13
“CDK4 and CDK6 function during the G1 phase to push quiescent cells that have entered the cell cycle, or proliferating cells that have completed mitosis, toward the S phase [17].”
BackgroundSun, L., Liu, Z., Wu, Z., Wu, Z., Qiu, B., Liu, S., Hu, J., & Yin, X. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111279 · Cited by 13
Kao, W.-H., Chiu, K., Tsai, S. C., Teng, C. J., Oner, M., Lai, C., Hsieh, J., Lin, C., Wang, H., Chen, M., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167568 · Cited by 13
Identification of novel cyclin-dependent kinase 4/6 inhibitors from marine natural products
Debnath, A., Mazumder, R., Singh, A. K., & Singh, R. K. (2025) · PLoS ONE · doi:10.1371/journal.pone.0313830 · Cited by 13
“Their overactivation is a common issue in various cancers, including breast cancer, leading to uncontrolled cell division and tumor growth [7].”
Sanglikar, G., & Tengli, A. K. (2025) · Results in Chemistry · doi:10.1016/j.rechem.2025.102210 · Cited by 13
Rudolph, J., Hoeflich, K. P., & Dar, A. C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01411-9 · Cited by 13
“The development of selective CDK2 inhibitors has been hampered by the high structural similarity of ATP-binding pockets across the CDK family 150 .”
Wu, Y., Ying, H., Xu, L., Cheng, G., Chen, J., Hu, Y., Liu, T., & Dong, X. (2018) · Archiv der Pharmazie · doi:10.1002/ardp.201700381 · Cited by 13
Rodat, T., Krebs, M., Döbber, A., Jansen, B., Steffen‐Heins, A., Schwarz, K., & Peifer, C. (2020) · Photochemical & Photobiological Sciences · doi:10.1039/d0pp00097c · Cited by 13
An evaluation of palbociclib as a breast cancer treatment option: a current update
Gallanis, G. T., Pericas, R. I., Riegel, A. T., & Pohlmann, P. R. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1838485 · Cited by 14
DNA damage response proteins synergistically affect the cancer prognosis and resistance
Sharma, M., Anand, P., Padwad, Y. S., Dogra, V., & Acharya, V. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.11.033 · Cited by 13
Metadata
- Authors
- Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S.
- Affiliations
- Institute of Cancer Research (GB)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Royal Marsden NHS Foundation Trust (GB)
- Corresponding author
- Knudsen, Erik S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-01-30
- Volume
- 14
- Issue
- 2
- Pages
- 130-146
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4480421
- OpenAlex
- W2057272791
- Cited by
- 1,767
- References
- 210
- Citations by year
- 2026: 100 · 2025: 157 · 2024: 157 · 2023: 170 · 2022: 180 · 2021: 200 · 2020: 185 · 2019: 148 · 2018: 150 · 2017: 161 · 2016: 112 · 2015: 46
- FWCI
- 27.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Consortium canadien en neurodégénérescence associée au vieillissement
- Cancer Research UK (16642)
- National Cancer Institute (R01CA129134, CA129134, CA188650, R01CA188650, CA163863, R01CA163863)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin-dependent kinases, cyclin-dependent kinase inhibitors, CDK4, CDK6, CDK2, CDK1, cell cycle regulation, G1 phase, chromosome stability, S phase, anticancer drug development, clinical trials, patient stratification, kinase selectivity
- MeSH terms
- Animals, Antineoplastic Agents, Cell Cycle, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Molecular Structure, Signal Transduction, Gene Expression Regulation, Neoplastic, Cyclin-Dependent Kinases, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.